journal
MENU ▼
Read by QxMD icon Read
search

Expert Review of Neurotherapeutics

journal
https://www.readbyqxmd.com/read/28343407/what-are-the-complications-and-emerging-strategies-for-preventing-depression-following-traumatic-brain-injury
#1
Melissa Jones, Laura Acion, Ricardo E Jorge
Depression is a common and disabling complication of traumatic brain injury (TBI). The high rates of post-TBI depression (PTBID) make this condition an important candidate for selective preventive interventions. Areas covered: The authors recently reported on the efficacy of sertraline, a selective serotonin reuptake inhibitor (SSRI), for the prevention of new cases of depression in the first six months after TBI. The authors review this and other studies on preventive strategies in PTBID as ascertained from a PubMed and citation search...
March 27, 2017: Expert Review of Neurotherapeutics
https://www.readbyqxmd.com/read/28335645/treatment-of-sleep-disorders-in-youth-with-adhd-what-is-the-evidence-from-randomised-controlled-trials-and-how-should-the-field-move-forward
#2
Samuele Cortese, Marco Angriman
No abstract text is available yet for this article.
March 24, 2017: Expert Review of Neurotherapeutics
https://www.readbyqxmd.com/read/28293960/moving-forward-how-depression-heterogeneity-hinders-progress-in-treatment-and-research
#3
E I Fried
No abstract text is available yet for this article.
March 22, 2017: Expert Review of Neurotherapeutics
https://www.readbyqxmd.com/read/28277802/oxycodone-extended-release-capsules-for-the-treatment-of-chronic-pain
#4
Sebastiano Mercadante
As a consequence of greater prescription opioid utilization, there has been the parallel increase in misuse, abuse, and overdose, which are serious risks. Associated new formulations may be safer. Areas covered: The introduction of abuse-deterrent opioid formulations and continuous programs to improve opioid prescribing practices may limit the opioid abuse and its consequences. Oxycodone extended release capsules are an extended-release (ER), microsphere-in-capsule abuse-deterrent-formulation designed to retain its extended-release properties following tampering or misuse (e...
March 10, 2017: Expert Review of Neurotherapeutics
https://www.readbyqxmd.com/read/28092989/therapeutic-complement-inhibition-a-promising-approach-for-treatment-of-neuroimmunological-diseases
#5
Kjara S Pilch, Peter J Spaeth, Nobuhiro Yuki, Benjamin R Wakerley
Autoimmunity is an important cause of disease both in the central and peripheral nervous systems. Aetiologies and clinical manifestations are complex and heterogeneous. Inappropriate control of complement activation at inappropriate sites has been recognized as a major determinant in several neurological conditions, including Guillain-Barré syndrome and neuromyelitis optica. In each case pathogenesis is thought to be associated with generation of autoantibodies which upon binding guide activation of the complement system to self-tissue...
March 6, 2017: Expert Review of Neurotherapeutics
https://www.readbyqxmd.com/read/28128002/ketamine-for-the-treatment-of-super-refractory-status-epilepticus-not-quite-yet
#6
Frederic Dorandeu
No abstract text is available yet for this article.
February 6, 2017: Expert Review of Neurotherapeutics
https://www.readbyqxmd.com/read/28132567/will-the-proteus-sensor-enhance-adherence-to-aripiprazole-or-other-antipsychotics
#7
Prakash Masand, Changsu Han, Chi-Un Pae
No abstract text is available yet for this article.
February 3, 2017: Expert Review of Neurotherapeutics
https://www.readbyqxmd.com/read/28132569/the-challenges-of-developing-a-gene-therapy-for-amyotrophic-lateral-sclerosis
#8
Muhibullah Sayed Tora, Orion Paul Keifer, Jason John Lamanna, Nicholas M Boulis
No abstract text is available yet for this article.
January 30, 2017: Expert Review of Neurotherapeutics
https://www.readbyqxmd.com/read/28092469/investigational-drugs-in-recent-clinical-trials-for-treatment-resistant-depression
#9
Ricardo P Garay, Carlos A Zarate, Thomas Charpeaud, Leslie Citrome, Christoph U Correll, Ahcène Hameg, Pierre-Michel Llorca
The authors describe the medications for treatment-resistant depression (TRD) in phase II/III of clinical development in the EU and USA and provide an opinion on how current treatment can be improved in the near future. Areas covered: Sixty-two trials were identified in US and EU clinical trial registries that included six investigational compounds in recent phase III development and 12 others in recent phase II clinical trials. Glutamatergic agents have been the focus of many studies. A single intravenous dose of the glutamatergic modulator ketamine produces a robust and rapid antidepressant effect in persons with TRD; this effect continues to remain significant for 1 week...
January 29, 2017: Expert Review of Neurotherapeutics
https://www.readbyqxmd.com/read/28128996/endogenous-repair-and-development-inspired-therapy-of-neurodegeneration-in-progressive-multiple-sclerosis
#10
Ethan Hollingsworth, Jamil Khouri, Jaime Imitola
In recent years, there has been progress in understanding the etiology and immune mechanisms of multiple sclerosis (MS). However, for most, once the diagnosis is made, significant pathology is already present in the central nervous system (CNS), and in many, this leads to neurodegeneration, which accumulates in disability. Although, the mechanisms of such progression are poorly understood, new data suggest lack of remyelination paired with dysfunction of neurons along with stem and progenitor cells as the basis and recent developmental studies suggest that CNS repair processes share mechanisms with development...
January 27, 2017: Expert Review of Neurotherapeutics
https://www.readbyqxmd.com/read/27983884/extra-motor-abnormalities-in-amyotrophic-lateral-sclerosis-another-layer-of-heterogeneity
#11
P A McCombe, N R Wray, R D Henderson
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease defined by the presence of muscle weakness. The motor features of disease are heterogeneous in site of onset and progression. There are also extra-motor features in some patients. The genetic basis for extra-motor features is uncertain. The heterogeneity of ALS is an issue for clinical trials. Areas covered: This paper reviews the range and prevalence of extra-motor features associated with ALS, and highlights the current information about genetic associations with extra-motor features...
January 3, 2017: Expert Review of Neurotherapeutics
https://www.readbyqxmd.com/read/28005435/is-there-a-weight-neutral-second-generation-antipsychotic-for-bipolar-disorder
#12
Fang Fang, Zuowei Wang, Renrong Wu, Joseph R Calabrese, Keming Gao
Antipsychotic-induced weight gain (WG) and metabolic abnormalities are major concerns. This review was untaken to answer if there is a weight-neutral second-generation antipsychotic for bipolar disorder (BPD). Areas covered: English-language literature in MEDLINE was searched with the keywords of antipsychotic/second-generation antipsychotic or generic/brand name of second-generation antipsychotic, and BPD/mania/depression or bipolar maintenance, and safety/tolerability or WG/weight increase, and randomized, placebo-controlled trial...
January 2, 2017: Expert Review of Neurotherapeutics
https://www.readbyqxmd.com/read/28081625/an-unsound-aan-practice-advisory-on-poststroke-etanercept
#13
Ian A Clark
No abstract text is available yet for this article.
March 2017: Expert Review of Neurotherapeutics
https://www.readbyqxmd.com/read/28001435/how-should-physical-exercise-be-used-in-schizophrenia-treatment
#14
Alison R Yung, Joseph Firth
No abstract text is available yet for this article.
March 2017: Expert Review of Neurotherapeutics
https://www.readbyqxmd.com/read/27813429/clinical-utility-of-datscan%C3%A2-imaging-in-the-evaluation-of-patients-with-parkinsonism-a-us-perspective
#15
Stuart H Isaacson, Stanley Fisher, Fiona Gupta, Neal Hermanowicz, Daniel E Kremens, Mark F Lew, Kenneth Marek, Rajesh Pahwa, David S Russell, John Seibyl
Single photon emission computed tomography (SPECT) with Ioflupane I123 injection (DaTscan™) was approved by the Food and Drug Administration in 2011 for striatal dopamine transporter visualization to assist in the evaluation of adult patients with suspected parkinsonian syndromes. While brain SPECT imaging using DaTscan is a covered service under Medicare policy, there is a lack of consensus on its role in routine clinical practice in the US. Areas covered: To address this issue, an expert group of US-based movement disorders neurologists convened to discuss the clinical utility of DaTscan in movement disorders practices within the US...
March 2017: Expert Review of Neurotherapeutics
https://www.readbyqxmd.com/read/27690672/myasthenia-gravis-recent-advances-in-immunopathology-and-therapy
#16
John-Ih Lee, Sebastian Jander
Myasthenia gravis is the most frequent acquired disorder of neuromuscular transmission. In the majority of cases, pathogenic antibodies against components of the postsynaptic muscle endplate membrane can be detected. In recent years there have been significant advances in the pathophysiological understanding and therapy of the disease. Areas covered: PubMed searches were conducted for the term 'myasthenia gravis' cross-referenced with the terms 'immunology', 'subgroups', 'antibody', 'ocular', 'thymoma', 'treatment' and 'thymectomy'...
March 2017: Expert Review of Neurotherapeutics
https://www.readbyqxmd.com/read/27687685/treatment-of-epilepsy-in-patients-with-alzheimer-s-disease
#17
Filippo Sean Giorgi, Melania Guida, Andrea Vergallo, Ubaldo Bonuccelli, Gaetano Zaccara
Epilepsy is significantly more frequent in AD patients than in age-matched controls, even though the true extent of the phenomenon is not clear yet. Areas covered: In this review, we describe in detail the available data on the pharmacological treatment of epilepsy in patients with AD. We also briefly describe general principles of AEDs use in elderly, as well as the potential cognitive profile of AEDs and safety of concomitant psychotropic drugs in patients with epilepsy and AD. Expert commentary: As some preclinical data suggest a role of epileptiform discharges in cognitive decline in AD, a prompt diagnosis and treatment of seizures in these patients should be pursued...
March 2017: Expert Review of Neurotherapeutics
https://www.readbyqxmd.com/read/27677316/perioperative-management-of-parkinson-s-disease
#18
Umer Akbar, Arlet G Kurkchubasche, Joseph H Friedman
Guidelines for the management of Parkinson's disease (PD) patients in the perioperative setting are lacking. Areas covered: Here we review potential problems that may arise when PD patients are undergoing an operation. We also review the literature, where available, and provide our expert opinion and recommendations based on experience. Expert commentary: Elderly patients with PD are especially prone to complications in the perioperative setting. Extreme caution must be used to ensure appropriate medication administration, transition to non-oral agents, if indicated, and early mobilization to achieve rapid recovery after surgery...
March 2017: Expert Review of Neurotherapeutics
https://www.readbyqxmd.com/read/27659841/neuroprogression-and-illness-trajectories-in-bipolar-disorder
#19
Natália S Kapczinski, Benson Mwangi, Ryan M Cassidy, Diego Librenza-Garcia, Mariane Bagatin Bermudez, Márcia Kauer-Sant'anna, Flávio Kapczinski, Ives Cavalcante Passos
The longitudinal course of bipolar disorder is highly variable, and a subset of patients seems to present a progressive course associated with brain changes and functional impairment. Areas covered: We discuss the theory of neuroprogression in bipolar disorder. This concept considers the systemic stress response that occurs within mood episodes and late-stage deficits in functioning and cognition as well as neuroanatomic changes. We also discuss treatment refractoriness that may take place in some cases of bipolar disorder...
March 2017: Expert Review of Neurotherapeutics
https://www.readbyqxmd.com/read/27644548/management-and-therapeutic-perspectives-in-amyotrophic-lateral-sclerosis
#20
Stéphane Mathis, Philippe Couratier, Adrien Julian, Jean-Michel Vallat, Philippe Corcia, Gwendal Le Masson
Amyotrophic lateral sclerosis (ALS) is a fatal progressive neurodegenerative disorder affecting both upper and lower motor neurons. Despite much research and effort, no clear insights into a unifying hypothesis for the pathogenesis has so far emerged for this disease. Areas covered: We review the main pathophysiological hypotheses and the potential therapeutic targets in ALS, as well as the management of these patients (in order to improve their survival and quality of life). Expert commentary: ALS is a complex neurodegenerative disease, these days considered as a multisystem disorder with predominant motor symptoms (and various clinical forms)...
March 2017: Expert Review of Neurotherapeutics
journal
journal
39882
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"